Drugs / HRS2398
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05144061 | Dec 2021 → Feb 2024 | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06439589 | Jun 2024 → Dec 2025 overdue | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS2398 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06439589 ↗ |
| Route | Oral | “Oral administration” NCT05144061 ↗ |